Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
folinic acid + 5-fluorouracil + oxaliplatin + irinotecan
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FOLFOXIRI is a chemotherapy combination regimen consisting of four drugs: folinic acid (also known as leucovorin or calcium folinate), 5-fluorouracil (5-FU), oxaliplatin, and irinotecan. It is primarily used for the treatment of advanced or metastatic colorectal cancer. The regimen works by combining three cytotoxic agents—fluorouracil, oxaliplatin, and irinotecan—which target rapidly dividing cancer cells through different mechanisms. Folinic acid enhances the effectiveness of 5-fluorouracil by stabilizing its binding to thymidylate synthase, thereby increasing cytotoxicity against tumor cells. Oxaliplatin is a platinum-based agent that causes DNA crosslinking and apoptosis; irinotecan inhibits topoisomerase I, leading to DNA damage; and 5-fluorouracil acts as an antimetabolite inhibiting thymidylate synthase and interfering with DNA synthesis. This combination has been shown in clinical trials to improve progression-free survival in patients with metastatic colorectal cancer compared to doublet regimens[2][3][7].
- Brand names
- FOLFOXIRI
- Other names
- FOLFOXIRIfluorouracil leucovorin oxaliplatin irinotecanfolinic acid fluorouracil oxaliplatin irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on folinic acid + 5-fluorouracil + oxaliplatin + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on folinic acid + 5-fluorouracil + oxaliplatin + irinotecan.